Remove 2023 Remove Licensing Remove Marketing Remove Settlement
article thumbnail

Formycon/Fresenius Kabi and Samsung Bioepis Settlements with J&J and Janssen Biotech regarding Ustekinumab

LexBlog IP

On August 7, 2023, Formycon AG and Fresenius Kabi announced that they have reached a settlement with Johnson & Johnson (“J&J”) in the United States relating to FYB202, a proposed ustekinumab biosimilar to STELARA®, marketed by J&J.

article thumbnail

Biocon Settles with Janssen, Securing U.S. Market Entry Date for Ustekinumab Biosimilar

LexBlog IP

On February 29, Biocon Biologics Ltd announced that it signed a settlement and license agreement with Janssen Biotech Inc. As part of the settlement, Biocon has agreed to terminate the pending inter partes review of Janssen and J&J’s U.S. Amgen secured a U.S. The post Biocon Settles with Janssen, Securing U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Photo Licensing Service Qualifies for DMCA 512(c) Safe Harbor–McGucken v. ShutterStock

Technology & Marketing Law Blog

He claims that third party “contributors” uploaded his copyrighted photos to ShutterStock as part of ShutterStock’s licensing program. Specifically, McGucken claims that a total of 337 images were uploaded, of which 165 were downloaded and that led to 938 licenses. Otherwise, this case appears to be economically irrational.

article thumbnail

Year in Review: Top Regulatory Developments of 2023

LexBlog IP

As we kick off 2024, we reflect on regulatory developments in the biologics and biosimilars space in 2023. Below are some of the top regulatory developments from 2023. Janssen and Amgen settled their BPCIA litigation regarding Amgen’s ustekinumab biosimilar product in May 2023.

article thumbnail

Year in Review: Top Legal Developments of 2023

LexBlog IP

As we settle into 2024, we reflect on the significant legal developments of 2023 that hold potential impact on the biologics and biosimilars market. The following is a recap of some of the top five legal decisions and developments in the biosimilars and biologics space in 2023 that we covered on the Big Molecule Watch.

article thumbnail

Year in Review: Top-Five U.S. Biosimilar Market Developments of 2021

LexBlog IP

biosimilar market developments of 2021. market, as each biosimilar applicant has entered into a license agreement with AbbVie that permits the applicant to begin U.S. marketing only after a specified date in 2023. CYLTEZO is not scheduled to launch until July 1, 2023, pursuant to a settlement agreement with AbbVie.

article thumbnail

Humira’s End of Reign

JD Supra Law

settlement agreement with Abbvie that grants Alvotech non-exclusive rights to market AVT02 (adalimumab) in the U.S starting July 1, 2023. On March 8, 2022, Alvotech announced that it has executed a U.S.